Positive News SentimentPositive NewsNASDAQ:PRCT PROCEPT BioRobotics (PRCT) Stock Price, News & Analysis $40.34 -0.46 (-1.13%) Closing price 04:00 PM EasternExtended Trading$39.99 -0.35 (-0.86%) As of 04:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About PROCEPT BioRobotics Stock (NASDAQ:PRCT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get PROCEPT BioRobotics alerts:Sign Up Key Stats Today's Range$40.10▼$41.1450-Day Range$38.41▼$60.2252-Week Range$37.12▼$103.81Volume688,365 shsAverage Volume1.02 million shsMarket Capitalization$2.24 billionP/E RatioN/ADividend YieldN/APrice Target$74.88Consensus RatingModerate Buy Company Overview PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California. Read More PROCEPT BioRobotics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks71st Percentile Overall ScorePRCT MarketRank™: PROCEPT BioRobotics scored higher than 71% of companies evaluated by MarketBeat, and ranked 297th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingPROCEPT BioRobotics has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoveragePROCEPT BioRobotics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about PROCEPT BioRobotics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for PROCEPT BioRobotics are expected to grow in the coming year, from ($1.75) to ($1.27) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of PROCEPT BioRobotics is -26.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PROCEPT BioRobotics is -26.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPROCEPT BioRobotics has a P/B Ratio of 5.82. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about PROCEPT BioRobotics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.46% of the float of PROCEPT BioRobotics has been sold short.Short Interest Ratio / Days to CoverPROCEPT BioRobotics has a short interest ratio ("days to cover") of 6.8.Change versus previous monthShort interest in PROCEPT BioRobotics has recently increased by 4.40%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPROCEPT BioRobotics does not currently pay a dividend.Dividend GrowthPROCEPT BioRobotics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted13.46% of the float of PROCEPT BioRobotics has been sold short.Short Interest Ratio / Days to CoverPROCEPT BioRobotics has a short interest ratio ("days to cover") of 6.8.Change versus previous monthShort interest in PROCEPT BioRobotics has recently increased by 4.40%, indicating that investor sentiment is decreasing. News and Social Media4.2 / 5News Sentiment1.53 News SentimentPROCEPT BioRobotics has a news sentiment score of 1.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 19 news articles for PROCEPT BioRobotics this week, compared to 8 articles on an average week.Search Interest6 people have searched for PRCT on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.MarketBeat Follows3 people have added PROCEPT BioRobotics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, PROCEPT BioRobotics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,271,250.00 in company stock.Percentage Held by InsidersOnly 6.60% of the stock of PROCEPT BioRobotics is held by insiders.Percentage Held by Institutions89.46% of the stock of PROCEPT BioRobotics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about PROCEPT BioRobotics' insider trading history. Receive PRCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PROCEPT BioRobotics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PRCT Stock News HeadlinesPROCEPT BioRobotics (PRCT) Outlook Adjusted as System Replacement Forecasts ShiftAugust 22, 2025 | uk.finance.yahoo.comAnalyzing PROCEPT BioRobotics (NASDAQ:PRCT) and Thermo Fisher Scientific (NYSE:TMO)August 22, 2025 | americanbankingnews.comINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.August 28 at 2:00 AM | Traders Agency (Ad)Procept BioRobotics director buys 785K in common stockAugust 15, 2025 | msn.comProcept BioRobotics: Increasing Average Selling Price, Initiate At BuyAugust 14, 2025 | seekingalpha.comLeerink Partners Reiterates a Buy Rating on PROCEPT BioRobotics (PRCT)August 13, 2025 | msn.comPROCEPT BioRobotics Corporation (NASDAQ:PRCT) Q2 2025 Earnings Call TranscriptAugust 8, 2025 | msn.comPROCEPT BioRobotics Corporation (PRCT) Q2 2025 Earnings Call TranscriptAugust 7, 2025 | seekingalpha.comSee More Headlines PRCT Stock Analysis - Frequently Asked Questions How have PRCT shares performed this year? PROCEPT BioRobotics' stock was trading at $80.52 at the beginning of the year. Since then, PRCT stock has decreased by 49.9% and is now trading at $40.34. How were PROCEPT BioRobotics' earnings last quarter? PROCEPT BioRobotics Corporation (NASDAQ:PRCT) posted its earnings results on Wednesday, August, 6th. The company reported ($0.35) EPS for the quarter, beating analysts' consensus estimates of ($0.41) by $0.06. The business's revenue for the quarter was up 48.3% on a year-over-year basis. Read the conference call transcript. When did PROCEPT BioRobotics IPO? PROCEPT BioRobotics (PRCT) raised $126 million in an initial public offering on Wednesday, September 15th 2021. The company issued 5,500,000 shares at $22.00-$24.00 per share. Who are PROCEPT BioRobotics' major shareholders? PROCEPT BioRobotics' top institutional shareholders include Alliancebernstein L.P. (3.88%), Westfield Capital Management Co. LP (2.87%), Geode Capital Management LLC (2.35%) and State Street Corp (2.28%). Insiders that own company stock include Frederic H Moll, Reza Zadno, Morgan Colby Wood, Kevin Waters, Hisham Shiblaq, Alaleh Nouri and Antal Rohit Desai. View institutional ownership trends. How do I buy shares of PROCEPT BioRobotics? Shares of PRCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of PROCEPT BioRobotics own? Based on aggregate information from My MarketBeat watchlists, some other companies that PROCEPT BioRobotics investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), Netflix (NFLX), Tesla (TSLA), NVIDIA (NVDA), SPDR Dow Jones Industrial Average ETF Trust (DIA) and Meta Platforms (META). Company Calendar Last Earnings8/06/2025Today8/28/2025Next Earnings (Estimated)10/27/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED INSTRUMENTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:PRCT CIK1588978 Webwww.procept-biorobotics.com Phone650-232-7200FaxN/AEmployees430Year FoundedN/APrice Target and Rating Average Price Target for PROCEPT BioRobotics$74.88 High Price Target$99.00 Low Price Target$55.00 Potential Upside/Downside+83.5%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($1.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$91.41 million Net Margins-30.60% Pretax Margin-30.60% Return on Equity-23.73% Return on Assets-17.34% Debt Debt-to-Equity Ratio0.13 Current Ratio9.21 Quick Ratio7.86 Sales & Book Value Annual Sales$224.50 million Price / Sales10.11 Cash FlowN/A Price / Cash FlowN/A Book Value$6.93 per share Price / Book5.89Miscellaneous Outstanding Shares55,640,000Free Float51,964,000Market Cap$2.27 billion OptionableOptionable Beta1.05 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:PRCT) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredSmall Washington, DC Group Could Crash US StocksNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PROCEPT BioRobotics Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share PROCEPT BioRobotics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.